TY - JOUR
T1 - Cost-utility analysis of four common surgical treatment pathways for breast cancer
AU - Kouwenberg, Casimir A.E.
AU - Mureau, Marc A.M.
AU - Kranenburg, Leonieke W.
AU - Rakhorst, Hinne
AU - de Leeuw, Daniëlle
AU - Klem, Taco M.A.L.
AU - Koppert, Linetta B.
AU - Ramos, Isaac Corro
AU - Busschbach, Jan J.
N1 - Source of funding:
Funding received from the Esser Foundation. Prof. Dr. Busschbach is a member of the non-profit EuroQoL Group and receives financial compensation for managerial activities for the group. For the remaining authors, none were declared.
Publisher Copyright: © 2020
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Background: The aim was to evaluate the cost-utility of four common surgical treatment pathways for breast cancer: mastectomy, breast-conserving therapy (BCT), implant breast reconstruction (BR) and autologous-BR. Methods: Patient-level healthcare consumption data and results of a large quality of life (QoL) study from five Dutch hospitals were combined. The cost-effectiveness was assessed in terms of incremental costs and quality adjusted life years (QALYs) over a 10-year follow-up period. Costs were assessed from a healthcare provider perspective. Results: BCT resulted in comparable QoL with lower costs compared to implant-BR and autologous-BR and showed better QoL with higher costs than mastectomy (€17,246/QALY). QoL outcomes and costs of especially autologous-BR were affected by the relatively high occurrence of complications. If reconstruction following mastectomy was performed, implant-BR was more cost-effective than autologous-BR. Conclusion: The occurrence of complications had a substantial effect on costs and QoL outcomes of different surgical pathways for breast cancer. When this was taken into account, BCT was most the cost-effective treatment. Even with higher costs and a higher risk of complications, implant-BR and autologous-BR remained cost-effective over mastectomy. This pleas for adapting surgical pathways to individual patient preferences in the trade-off between the risks of complications and expected outcomes.
AB - Background: The aim was to evaluate the cost-utility of four common surgical treatment pathways for breast cancer: mastectomy, breast-conserving therapy (BCT), implant breast reconstruction (BR) and autologous-BR. Methods: Patient-level healthcare consumption data and results of a large quality of life (QoL) study from five Dutch hospitals were combined. The cost-effectiveness was assessed in terms of incremental costs and quality adjusted life years (QALYs) over a 10-year follow-up period. Costs were assessed from a healthcare provider perspective. Results: BCT resulted in comparable QoL with lower costs compared to implant-BR and autologous-BR and showed better QoL with higher costs than mastectomy (€17,246/QALY). QoL outcomes and costs of especially autologous-BR were affected by the relatively high occurrence of complications. If reconstruction following mastectomy was performed, implant-BR was more cost-effective than autologous-BR. Conclusion: The occurrence of complications had a substantial effect on costs and QoL outcomes of different surgical pathways for breast cancer. When this was taken into account, BCT was most the cost-effective treatment. Even with higher costs and a higher risk of complications, implant-BR and autologous-BR remained cost-effective over mastectomy. This pleas for adapting surgical pathways to individual patient preferences in the trade-off between the risks of complications and expected outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85098207460&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2020.11.130
DO - 10.1016/j.ejso.2020.11.130
M3 - Article
C2 - 33349523
AN - SCOPUS:85098207460
VL - 47
SP - 1299
EP - 1308
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
SN - 0748-7983
IS - 6
ER -
